Patent intelligence · US
US 12201701
Vegetable oil-derived contrast agent with high stability and preparation method thereof
Vegetable oil-derived contrast agent with high stability and preparation method thereof
Patent details — US 12201701
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 21, 2025
- Expiration
- Jan 16, 2045
- Applicant
- ENGAIN CO., LTD.
- Claims
- 4
- CPC classes
- A61K, A61K49/0438
Quick answer
US 12201701 (Vegetable oil-derived contrast agent with high stability and preparation method thereof) is held by ENGAIN CO., LTD.. Status: granted. Granted Jan 21, 2025. Expires Jan 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ENGAIN CO., LTD.
- Grant date
- Expiration
- Claims
- 4
- CPC classes
- A61K, A61K49/0438
More from ENGAIN CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12370232
Use of polyphenol containing sugar cane extracts for preventing, improving or treating a skin condition
granted -
US 11730178
Extraction method
granted -
US 11311581
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
granted -
US 11020365
Mixture of fatty acids for use in the treatment of inflammatory pathologies
granted -
US 10960000
Abuse resistant pharmaceutical compositions
granted -
US 10646523
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
granted -
US 10213389
Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
granted
Frequently asked questions
What is US patent 12201701?
US 12201701 (Vegetable oil-derived contrast agent with high stability and preparation method thereof) is held by ENGAIN CO., LTD.. Status: granted. Granted Jan 21, 2025. Expires Jan 16, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12201701?
ENGAIN CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.
When does US 12201701 expire?
Our index shows an expiration date of Jan 16, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.